| Literature DB >> 29275977 |
Alan J Thompson1, Brenda L Banwell2, Frederik Barkhof3, William M Carroll4, Timothy Coetzee5, Giancarlo Comi6, Jorge Correale7, Franz Fazekas8, Massimo Filippi9, Mark S Freedman10, Kazuo Fujihara11, Steven L Galetta12, Hans Peter Hartung13, Ludwig Kappos14, Fred D Lublin15, Ruth Ann Marrie16, Aaron E Miller15, David H Miller17, Xavier Montalban18, Ellen M Mowry19, Per Soelberg Sorensen20, Mar Tintoré21, Anthony L Traboulsee22, Maria Trojano23, Bernard M J Uitdehaag24, Sandra Vukusic25, Emmanuelle Waubant26, Brian G Weinshenker27, Stephen C Reingold28, Jeffrey A Cohen29.
Abstract
The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research and clinical practice. Scientific advances in the past 7 years suggest that they might no longer provide the most up-to-date guidance for clinicians and researchers. The International Panel on Diagnosis of Multiple Sclerosis reviewed the 2010 McDonald criteria and recommended revisions. The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation. The following changes were made: in patients with a typical clinically isolated syndrome and clinical or MRI demonstration of dissemination in space, the presence of CSF-specific oligoclonal bands allows a diagnosis of multiple sclerosis; symptomatic lesions can be used to demonstrate dissemination in space or time in patients with supratentorial, infratentorial, or spinal cord syndrome; and cortical lesions can be used to demonstrate dissemination in space. Research to further refine the criteria should focus on optic nerve involvement, validation in diverse populations, and incorporation of advanced imaging, neurophysiological, and body fluid markers.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29275977 DOI: 10.1016/S1474-4422(17)30470-2
Source DB: PubMed Journal: Lancet Neurol ISSN: 1474-4422 Impact factor: 44.182